🔗 Share this article

As the US undertakes historic adjustments to its vaccine recommendations, a particular individual has emerged unexpectedly: Høeg, an American of Danish descent sports physician and public health researcher who first made her name by casting doubt on coronavirus vaccines in the pandemic and has zeroed in on alleged fatalities after Covid immunization in her brief position at the FDA.

Planned Shifts to Pediatric Vaccine Program

Health officials were set to reveal major changes to the pediatric immunization program in December, aligning the US with Denmark’s national calendar, according to reports – a substantial departure that would place the US out of step with much of the global community with insufficient data for benefit. The planned update has been postponed until the next year.

In place of Vinay Prasad, Høeg is listed to address the audience at the meeting. She was recently named acting director of the FDA’s drug evaluation center, the fifth appointee to lead the center this year.

A New Direction at the Regulatory Body

The acting appointment may indicate a tighter collaboration between the drug and vaccine centers as Høeg and Prasad solidify control at the regulatory agency – and it suggests a greater focus upon reevaluating already-approved vaccines at the FDA.

The new acting director has often pushed for ending certain pediatric shot schedules in the US so as to align more like Denmark, a country with nationalized medicine and a citizenry about the population of the state of Wisconsin.

So far statements, she has kept her attention on immunizations – typically the responsibility of Dr. Prasad, chief of the FDA’s vaccine center – rather than pharmaceutical oversight.

Concerns Over Qualifications

The appointee has no apparent experience in drug development, approval processes or administrative roles, which has been typical for past heads of the biologics center. She has worked at the FDA as a key advisor to the commissioner and the vaccine center since March.

“It seems she lacks to have any of the qualifications” for leading the pharmaceutical oversight division, remarked a neurologist and psychiatrist. “She lacks experience running a scientific study. She is not versed in leading a large organization. She has no expertise in industry regulation.”

Previous directors of the center would “grasp legal statutes and the underlying principles of drug development”, commented Dr. Janet Woodcock. “Clearly, she doesn’t have the sort of resume that previous people who led the center have had.”

This division has an enormous portfolio at the FDA, the former commissioner emphasized.

“Many people just pays attention on the novel medication approvals, but the off-patent medication office authorizes a multitude of off-brand pharmaceuticals. There is also a biosimilars program, non-prescription drug unit and so forth, and each of these need to be supervised,” Woodcock explained. “The responsibility you don’t keep your eye on, that is precisely what that I always told people is going to come back to haunt you.”

Furthermore, a substantial management aspect to the job, which supervises in excess of 5,000 employees. “It is a huge leadership role, if you execute it properly,” she added.

Agency Reaction and Controversial Programs

Regarding questions about Dr. Høeg's credentials and whether this assignment represents increased cooperation among agency officials on immunizations, a representative responded that the “inquiries stem from incorrect presumptions”.

“Her resume is consistent with the duties of her role,” the representative explained, noting the time Dr. Høeg spent counseling the FDA commissioner on “drug safety and regulatory science, including computational safety modeling and shot safety tracking”.

As the temporary head, Høeg inherits the commissioner’s recently launched expedited review system, a disputed one-day drug-approval program that allegedly troubled her former heads. “By what process are these drugs being selected for this expedited pathway? Who takes the decisions?” Howard said. “There is a lot of confidentiality going on at the regulatory body right now.”

Overall, he remarked, “the FDA looks to be trending towards more relaxed regulations of pharmaceuticals, with the exception of immunizations.”

Established Past Work on Immunizations

Regarding vaccines, Høeg has a more established, if problematic, past, critics have noted. She released a analysis using non-validated volunteer-provided data to estimate the frequency of heart inflammation following COVID-19 vaccination. She consulted for the Florida top health official Dr. Joseph Ladapo, who reportedly have modified findings to indicate Covid vaccines are more dangerous than they are.

Included in her “wish list” for the new administration featured revising guidelines for novel immunizations and ending “non-essential” immunizations, she stated post-election on a podcast. At the agency, Dr. Høeg has reportedly suggested barring young men from getting COVID-19 vaccines.

“She is an all-around ideologue who starts off with her conclusions and tailors the evidence to accommodate the data in a highly disingenuous, fraudulent way,” Dr. Howard said.

Taking Control and a “Campaign of Retribution”

Høeg aligned with other contrarians, {like|